| pubmed-article:1387935 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1387935 | lifeskim:mentions | umls-concept:C0599779 | lld:lifeskim |
| pubmed-article:1387935 | lifeskim:mentions | umls-concept:C0003467 | lld:lifeskim |
| pubmed-article:1387935 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:1387935 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:1387935 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:1387935 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1387935 | pubmed:dateCreated | 1992-10-15 | lld:pubmed |
| pubmed-article:1387935 | pubmed:abstractText | The effects of different doses of buspirone, 3-dipropyl-amino-5-hydrochromar (NDO 008) and 8-hydroxydipropyl-aminotetralin (8-OH-DPAT) (administered intraperitoneally) were studied in tests of anxiolytic and antidepressant action in rats. These tests included the elavated plus maze test, the forced swim test, stress-induced suppression of open-field behavior, and the differential-reinforcement-of-low-rates-of-behaviour-72 sec (DRL 72 s) test. Buspirone (0.125 mg/kg) and NDO 008 (1.0 to 2.0 mg/kg) produced anxiolytic activity in the elevated plus maze, whereas 8-OH-DPAT did not in the doses employed. All three compounds increased activity in the forced swim test, although buspirone did so at a lower dose than NDO 008 and 8-OH-DPAT. In the stress-induced suppression test of open field activity all three compounds induced an antidepressant-like effect at different doses dependent on whether footshock (stressor) was presented 24 hr before or just prior to the open-field test. All three compounds even caused some reduction of activity in the non-shocked rats. 8-OH-DPAT (1.0 mg/kg) produced a significant and reliable increase in the Reinforcement/Response rate quotient in the DRL 72s test. These diverse results may provide an indication of potential clinical efficacy of the 5-HT1A agonists in the treatment of anxiety and depression. | lld:pubmed |
| pubmed-article:1387935 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1387935 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1387935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1387935 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1387935 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1387935 | pubmed:issn | 0901-9928 | lld:pubmed |
| pubmed-article:1387935 | pubmed:author | pubmed-author:KostowskiWW | lld:pubmed |
| pubmed-article:1387935 | pubmed:author | pubmed-author:ArcherTT | lld:pubmed |
| pubmed-article:1387935 | pubmed:author | pubmed-author:DyrWW | lld:pubmed |
| pubmed-article:1387935 | pubmed:author | pubmed-author:JärbeTT | lld:pubmed |
| pubmed-article:1387935 | pubmed:author | pubmed-author:KrzascikPP | lld:pubmed |
| pubmed-article:1387935 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1387935 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:1387935 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1387935 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1387935 | pubmed:pagination | 24-30 | lld:pubmed |
| pubmed-article:1387935 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:meshHeading | pubmed-meshheading:1387935-... | lld:pubmed |
| pubmed-article:1387935 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1387935 | pubmed:articleTitle | 5-Hydroxytryptamine1A receptor agonists in animal models of depression and anxiety. | lld:pubmed |
| pubmed-article:1387935 | pubmed:affiliation | Department of Pharmacology and Physiology of the Nervous System, Psychoneurological Institute, Warszawa, Poland. | lld:pubmed |
| pubmed-article:1387935 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1387935 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1387935 | lld:pubmed |
